全球抗体疗法市场规模、份额、趋势和成长分析报告（2026-2034年）

预计抗体疗法市场将从 2025 年的 3,164.7 亿美元成长到 2034 年的 1.0596 兆美元，2026 年至 2034 年的复合年增长率为 14.37%。

由于对标靶治疗的需求不断增长，全球抗体疗法市场正经历显着成长。单株抗体广泛应用于肿瘤学、自体免疫疾病和感染疾病领域。慢性病盛行率的上升和生物技术的进步正在推动市场扩张。

关键成长要素包括生物製剂产品线的扩张和研发投入的增加。製药公司正在开发具有更高特异性和更低副作用的新一代抗体。医疗保健支出的成长和有利的报销政策进一步刺激了需求。此外，抗体工程技术的进步也提高了治疗效果。

展望未来，生物相似药的研发和新型抗体製剂的出现可望为市场带来强劲成长动力。新兴市场生物製药可及性的提高也将创造成长机会。各公司正致力于创新给药方式和联合治疗，随着精准医疗的进步，全球抗体疗法市场预计将稳定成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球抗体疗法市场：依形式划分

• 市场分析、洞察与预测
• 单株抗体
• 多株抗体疗法
• 双特异性抗体
• 抗体片段
• 其他的

第五章 全球抗体疗法市场：依疾病领域划分

• 市场分析、洞察与预测
• 自体免疫疾病与发炎性疾病
• 肿瘤学
• 血液学
• 感染疾病
• 骨学
• 免疫学
• 神经病学
• 其他的

第六章：全球抗体疗法市场：依给药途径划分

• 市场分析、洞察与预测
• 静脉注射
• 皮下注射

第七章：全球抗体疗法市场：依来源划分

• 市场分析、洞察与预测
• 人类
• 人源化抗体
• 嵌合体
• 其他的

第八章 全球抗体疗法市场：依最终用户划分

• 市场分析、洞察与预测
• 医院
• 长期照护机构
• 其他的

第九章 全球抗体疗法市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第十章 竞争格局

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十一章：公司简介

• 主要公司的市占率分析
• 公司简介
  • F. Hoffmann-La Roche Ltd.（Switzerland）
  • AbbVie Inc.（US）
  • Johnson & Johnson（US）
  • Merck KGaA（Germany）
  • Bristol-Myers Squibb（US）
  • AstraZeneca（UK）
  • Sanofi（France）
  • Regeneron Pharmaceuticals, Inc.（US）
  • Novartis AG（Switzerland）
  • Amgen, Inc.（US）
  • Biogen Inc.（US）

The Antibody Therapeutics Market size is expected to reach USD 1059.60 Billion in 2034 from USD 316.47 Billion (2025) growing at a CAGR of 14.37% during 2026-2034.

The Global Antibody Therapeutics Market is witnessing substantial growth due to increasing demand for targeted treatments. Monoclonal antibodies are widely used in oncology, autoimmune diseases, and infectious diseases. Rising prevalence of chronic conditions and advancements in biotechnology are supporting market expansion.

Key growth drivers include expansion of biologics pipelines and increasing R&D investments. Pharmaceutical companies are developing next-generation antibodies with improved specificity and reduced side effects. Growing healthcare expenditure and favorable reimbursement policies are further boosting demand. Additionally, advancements in antibody engineering technologies are enhancing therapeutic efficacy.

Looking ahead, the market is expected to benefit from biosimilar development and novel antibody formats. Emerging markets improving access to biologic therapies will create growth opportunities. Companies are focusing on innovative delivery methods and combination therapies. As precision medicine continues to evolve, the Global Antibody Therapeutics Market is projected to grow steadily.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Format

• Monoclonal Antibody
• Polyclonal Antibody Therapy
• Bispecific Antibody
• Antibody Fragment
• Other

By Disease Areas

• Autoimmune & Inflammatory Diseases
• Oncology
• Hematology
• Infectious Diseases
• Osteology
• Immunology
• Neurology
• Other

By Route Of Administration

• Intravenous
• Subcutaneous

By Source

• Human
• Humanized
• Chimeric
• Other

By End User

• Hospitals
• Long-Term Care Facilities
• Other

COMPANIES PROFILED

• F HoffmannLa Roche Ltd Switzerland, AbbVie Inc US, Johnson Johnson US, Merck KGaA Germany, BristolMyers Squibb US, AstraZeneca UK, Sanofi France, Regeneron Pharmaceuticals, Inc US, Novartis AG Switzerland, Amgen, Inc US, Biogen Inc US
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTIBODY THERAPEUTICS MARKET: BY FORMAT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Format
• 4.2. Monoclonal Antibody Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Polyclonal Antibody Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Bispecific Antibody Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Antibody Fragment Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTIBODY THERAPEUTICS MARKET: BY DISEASE AREAS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Areas
• 5.2. Autoimmune & Inflammatory Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Hematology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Osteology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Immunology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTIBODY THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTIBODY THERAPEUTICS MARKET: BY SOURCE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Source
• 7.2. Human Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Humanized Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Chimeric Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ANTIBODY THERAPEUTICS MARKET: BY END USER 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast End User
• 8.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Long-Term Care Facilities Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ANTIBODY THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Format
  • 9.2.2 By Disease Areas
  • 9.2.3 By Route Of Administration
  • 9.2.4 By Source
  • 9.2.5 By End User
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Format
  • 9.3.2 By Disease Areas
  • 9.3.3 By Route Of Administration
  • 9.3.4 By Source
  • 9.3.5 By End User
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Format
  • 9.4.2 By Disease Areas
  • 9.4.3 By Route Of Administration
  • 9.4.4 By Source
  • 9.4.5 By End User
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Format
  • 9.5.2 By Disease Areas
  • 9.5.3 By Route Of Administration
  • 9.5.4 By Source
  • 9.5.5 By End User
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Format
  • 9.6.2 By Disease Areas
  • 9.6.3 By Route Of Administration
  • 9.6.4 By Source
  • 9.6.5 By End User
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL ANTIBODY THERAPEUTICS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 F. Hoffmann-La Roche Ltd. (Switzerland)
  • 11.2.2 AbbVie Inc. (US)
  • 11.2.3 Johnson & Johnson (US)
  • 11.2.4 Merck KGaA (Germany)
  • 11.2.5 Bristol-Myers Squibb (US)
  • 11.2.6 AstraZeneca (UK)
  • 11.2.7 Sanofi (France)
  • 11.2.8 Regeneron Pharmaceuticals, Inc. (US)
  • 11.2.9 Novartis AG (Switzerland)
  • 11.2.10 Amgen, Inc. (US)
  • 11.2.11 Biogen Inc. (US)